araag2/HINT huggingface dataset:
Clinical trial NCT00415246 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: triptorelin (decapeptyl®) - treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Reason stopped: 
    the preliminary data do not support the expected sustainable blood levels of triptorelin for a
    duration of 4 months in all patients.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must give written (personally signed and dated) informed consent before
             completing any study-related procedure, which means any assessment or evaluation that
             would not have formed part of the normal medical care of the patient

          -  Patient must be 18 years old or over

          -  Patient must have a histologically-confirmed diagnosis of locally advanced or
             metastatic prostate cancer or presenting a relapse after curative treatment which is
             amenable to androgen deprivation therapy

          -  Patient must have an estimated survival time of greater than 8 months according to the
             investigator's assessment

        Exclusion Criteria:

          -  Patient at risk of a serious complication in the case of tumour flare (vertebral
             metastases threatening spinal cord compression or with significant obstructive
             uropathy)

          -  Patient who underwent a previous surgical castration

          -  Prostate cancer therapy within 2 months of baseline visit

          -  Patient with testosterone level below 150 ng/dL at screening
Clinical trial NCT00451412 (phase 3, status: completed)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: certoparin, unfractionated heparin
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          1. Hospitalized medical patients 70 years of age or older

          2. Acute medical illness with significant decrease in mobility expected for at least 4
             days (patient bedridden or only able to walk short distances)

          3. written informed consent

        Exclusion Criteria:

          1. immobilization longer than 3 days prior to randomization

          2. prior major surgery, trauma or invasive procedure within the last 4 weeks including
             any injuries or operation of central nervous system

          3. expected major surgical or invasive procedure within the next 3 weeks after
             randomization

          4. LMWH/heparin administration longer than 48 hours in the 5 days prior to randomization

          5. immobilization due to cast or fracture

          6. indication for anticoagulatory or thrombolytic therapy

          7. acute symptomatic DVT / PE

          8. known hypersensitivity to any of the study drugs or drugs with similar chemical
             structures

          9. Acute or history of heparin induced thrombocytopenia type II (HIT II)

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00289978 (phase 3, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: fingolimod 1.25 mg, fingolimod 0.5 mg, placebo
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis

          -  Patients with a relapsing-remitting disease course

          -  Patients with EDSS score of 0-5.5

        Exclusion Criteria:

          -  Patients with other chronic disease of the immune system, malignancies, acute
             pulmonary disease, cardiac failure, etc.

          -  Pregnant or nursing women

        Other protocol-defined inclusion/exclusion criteria applied to this study.
Clinical trial NCT00402987 (phase 3, status: completed)
Conditions: pharyngitis
ICD codes: A54.5, J02.0, J31.2, B08.5, J02.9, A50.03, J02.8
Drugs: celecoxib, celecoxib, celecoxib, placebo
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient must have a diagnosis of pharyngitis with objective findings of
             tonsillo-pharyngitis.

          -  The patient is willing to take "nothing by mouth" including inhaled treatments except
             trial medication during the two hours while at the site and following trial drug
             administration (e.g. not smoking, food, drink, candy, lozenges, chewing gum). The
             patient will be allowed food and drink between hours 2 and 24, but no other oral or
             inhaled treatments such as smoking, lozenges, chewing gum. After the two hour
             assessment, the patients will be allowed food and drink within one half-hour following
             any hourly evaluations sore throat.

        Exclusion Criteria:

          -  The patient has used any analgesic/antipyretic within 1 dosing interval preceding
             administration of the first dose of trial medication.

          -  The patient anticipates using any inhaled therapy including beta-agonists (e.g.,
             ventolin) during the 24 hour trial period and, if used, has only used inhaled therapy
             on an intermittent basis in the week prior to the screening visit.
Clinical trial NCT01412944 (phase 3, status: completed)
Conditions: plaque-type psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
SMILES: CCO
Eligibility criteria:

        Inclusion criteria:

          -  Written Informed Consent must be obtained before any assessment is performed,

          -  Subject must be able to understand and communicate with the investigator and comply
             with the requirements of the study.

          -  Subjects must have participated in the study CAIN457A2304 and have achieved a partial
             response after twelve weeks of treatment with no major protocol deviations.

        A partial response is defined as having achieved ≥ PASI 50 but < 75 response.

        Exclusion criteria

          -  Pregnant women or lactating women

          -  Forms of psoriasis other than chronic plaque -type

          -  Ongoing use of prohibited psoriasis treatments

          -  Ongoing use of other non-psoriasis prohibited treatments

          -  Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor,
             except secukinumab in study CAIN457A2304

          -  Active ongoing inflammation diseases other than psoriasis that might confound the
             evaluation of the benefits of secukinumab therapy

          -  UV therapy or excessive exposure to sunlight
Clinical trial NCT00326053 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18 - 65 years of age

          -  Presenting at a study emergency department with an asthma exacerbation

        Exclusion Criteria:

          -  Admission to hospital

          -  Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled
             corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Clinical trial NCT00384189 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide, placebo, salbutamol
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Main Inclusion Criteria:

          -  History of asthma for at least 6 months

          -  Ability to show optimal use of MDI, including inhalation technique

          -  Lung function and reversibility within specified limits

        Main Exclusion Criteria:

          -  Concomitant severe diseases

          -  Diseases which are contraindications for the use of inhaled steroids

          -  Two or more inpatient hospitalizations for asthma within the last year

          -  Respiratory tract infection or asthma exacerbation within the last 30 days prior to
             entry into the study

          -  Use of systemic steroids within the last 30 days prior to inclusion (depot steroids 6
             weeks)

          -  Beginning of or change in immunotherapy within the last 6 months prior to inclusion

          -  Inability to follow the procedures of the study
Clinical trial NCT00311363 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: gen (xp13512), gen (xp13512), placebo
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with primary RLS, based on the International RLS Study Group Diagnostic
             Criteria.

        Exclusion Criteria:

          -  A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of
             RLS;

          -  Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's
             disease, Multiple Sclerosis, dyskinesias, and dystonias);

          -  Abnormal laboratory results, electrocardiogram (ECG) or physical findings;

          -  Pregnant or lactating women;

          -  Women of childbearing potential who are not practicing an acceptable method of birth
             control.
Clinical trial NCT01630135 (phase 3, status: completed)
Conditions: rhinitis, allergic, perennial
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1
Drugs: fluticasone furoate, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  6 to <15 years of age, male or eligible female (females of childbearing potential must
             commit to consistent and correct use of an acceptable method of birth control),
             outpatient

          -  Diagnosis of perennial allergic rhinitis: A positive test response to house dust
             and/or dust mites on serum antigen-specific IgE antibody test at Visit 1. One year or
             more clinical history of perennial allergic rhinitis. A positive test result on nasal
             eosinophil count at Visit 1/1A.

          -  Either subject's parent/guardian who signed ICF or subject is able to complete
             assessments on the patient diary through the study.

          -  ALT < 2xULN; alkaline phosphatase and bilirubin <= 1.5xULN

          -  Average of 3TNSS is >= 4.0 in the last consecutive 4 days prior to Visit 2.

          -  Completion of the patient diary on >= 3 days of the last consecutive 4 days prior to
             Visit 2

        Exclusion Criteria:

          -  Has a seasonal pollen as an allergen

          -  A nose disorder that could affect the assessment of the study medication or eye or
             nose surgery (within 3 months prior to Visit 1)

          -  Bacterial or viral infection of upper respiratory tract or eye

          -  Concurrent disease/abnormalities: Clinically significant uncontrolled disease

          -  Known hypersensitivity to corticosteroids or any excipients in the investigational
             product

          -  Has recent participation in a study and/or exposure to an investigational study drug
             within 3 months prior to Visit 1

          -  Use of the following medication and/or its combination drug within the specified time:

        Anti-IgE (Within 6 months prior to Visit 1), Immunosuppressive medications or Systemic
        corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks
        prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated,
        discontinued or changed its dose within 4 weeks prior to Visit 1

          -  Affiliation with Investigator's Site: Relative or employee

          -  History of alcohol or drug abuse, children in care or in the opinion of the
             investigator (sub-investigator), inappropriate to be enrolled in the study.

          -  Average of 3TNSS is >= 8.0 in the last consecutive 4 days prior to Visit 2.

          -  Bacterial or viral infection of upper respiratory tract or eye during the screening
             period.
Clinical trial NCT00395603 (phase 3, status: terminated)
Conditions: cardiovascular diseases, diabetes mellitus
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: mk0653a, ezetimibe (+) simvastatin / duration of treatment: 6 weeks, comparator: atorvastatin / duration of treatment: 6 weeks
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Reason stopped: 
    this study was terminated early due to poor recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Greater than 18 years of age

          -  Treated for at least the last 3 months with a daily dose of atorvastatin 40 mg

          -  Existing coronary heart disease and cholesterol > 4.0 mmol/l

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Elevated liver function tests

          -  Elevated creatine kinase (ck)

          -  Triglycerides (tg) > 4.5 mmol/l

          -  Drug or alcohol dependency within 6 months prior to visit 1

          -  Woman receiving hormonal therapy who have not been maintained on a stable dose and
             regimen for at least 8 weeks and are willing to continue the same regimen for the
             duration of the study

          -  Woman of childbearing potential not using an acceptable method of birth control

          -  Women who are pregnant or breast feeding
Clinical trial NCT00250679 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease, bronchitis, emphysema
ICD codes: J44.9, J44.1, J44.0, J20.9, J41.0, J41.1, J42, J20.2, J20.3, J20.6, J43.1, J43.2, J43.8, J43.9, J98.2, J98.3, T79.7XXS
Drugs: arformoterol tartrate inhalation solution, arformoterol 25 ųg bid, formoterol 12 ųg bid, placebo
SMILES: COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male and female subjects must be at least 35 years old at the time of consent

          -  Subjects must have a pre-established, documented primary clinical diagnosis of
             non-asthmatic COPD or are referred for diagnosis of non-asthmatic COPD

          -  Subjects must have a >=15 pack-year smoking history and a baseline breathlessness
             severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score)
             at Visits 1 and 2

          -  Female subjects <=65 years of age must have a negative serum pregnancy test, females
             of childbearing potential must be using an acceptable method of birth control

          -  Subjects must be in general good health.

        Key Exclusion criteria:

          -  Subjects with a history of asthma, with the exception of asthma diagnosed in childhood

          -  Subjects with a blood eosinophil count >5% of total white blood cell count

          -  Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1

          -  Subjects with a chest x-ray that suggests a diagnosis other than COPD (e.g.,
             diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other
             active/ongoing pulmonary conditions)
Clinical trial NCT00114777 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: cyclosporin a, belatacept less intensive regimen (li), belatacept more intensive regimen (mi)
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCO, CCO
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a first-time recipient of a kidney transplant from a deceased donor.

          -  Specific donor criteria

        Exclusion Criteria:

          -  Donor age <10 years

          -  Subjects receiving a concurrent solid organ or cell transplant (lung, heart, etc.)

          -  Subjects with a positive T-cell lymphocytotoxic crossmatch.

          -  Subjects who are positive for Hepatitis B or C, or HIV

          -  Active tuberculosis

          -  History of cancer in the last 5 years

          -  History of substance abuse

          -  Specific laboratory results are exclusionary

          -  Mammography suspicious for cancer

          -  Allergy to iodine

          -  For Long-term extension study-Subjects who have completed three years of study
             treatment (through Week 156)
Clinical trial NCT00294541 (phase 3, status: terminated)
Conditions: sickle cell disease, sickle cell anemia
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: ica-17043
SMILES: NC(=O)C(C1=CC=CC=C1)(C1=CC=C(F)C=C1)C1=CC=C(F)C=C1
Reason stopped: 
    lack of efficacy demonstrated in study ica-17043-10
  
Eligibility criteria:

        Inclusion Criteria:

          -  Successfully completed Study ICA-17043-10

          -  Discontinued Study 10 or 12 following the DMC recommendations because he/she was not
             on HU, and has since been on a stable dose of HU for at least 3 months prior to Day 1

          -  Male, or female not capable of becoming pregnant or using appropriate birth control

          -  Has willingly given written informed consent to participate in this study

        Exclusion Criteria:

          -  The subject, if female, has a positive urine pregnancy test on Day 1 (before entering
             study)

          -  The subject is presently unsuitable for participation in this long-term study
Clinical trial NCT01114737 (phase 3, status: completed)
Conditions: phenylketonuria
ICD codes: E70.0
Drugs: sapropterin dihydrochloride, placebo
SMILES: [H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 8 years of age

          -  Confirmed diagnosis of PKU

          -  Willing to continue current diet (typical diet for the 3 months prior to study entry)
             unchanged while participating in the study

          -  Willing and able to provide written, signed informed consent or in the case of
             subjects under the age of 18, provide written assent (if required) and written
             informed consent by a legally authorized representative after the nature of the study
             has been explained, and prior to any research-related procedures

          -  Sexually active subjects must be willing to use an acceptable method of contraception
             while participating in the study and for at least 30 days following the last dose of
             sapropterin dihydrochloride

          -  Females of childbearing potential must have a negative pregnancy test at screening and
             be willing to have additional pregnancy tests during the study. Females considered not
             of childbearing potential include those who have been in menopause at least 2 years,
             or had tubal ligation at least 1 year prior to screening, or have had total
             hysterectomy.

          -  Willing and able to comply with all study procedure

        Exclusion Criteria:

          -  Has known hypersensitivity to sapropterin dihydrochloride or its excipients

          -  Subject breastfeeding at screening or planning to become pregnant (subject or partner)
             at any time during the study

          -  Use of any investigational product or investigational medical device within 30 days
             prior to screening, or requirement for any investigational agent prior to the
             completion of all scheduled study assessments

          -  Received sapropterin dihydrochloride within 16 weeks of randomization

          -  Have initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤
             8 weeks prior to randomization

          -  Taking medication known to inhibit folate synthesis (eg, methotrexate)

          -  Any condition requiring treatment with levodopa or any PDE-5 inhibitor

          -  Concurrent disease or condition that would interfere with study participation,
             compliance or safety as determined by the Investigator

          -  Any condition that, in the view of the Investigator, places the subject at high risk
             of poor treatment compliance or of not completing the study